Autopsy report · NCT04794803

Reparixin in COVID-19 Pneumonia - Efficacy and Safety

“The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months after it had already started.
• Ran for about 9 months before it stopped.
• 56 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Dompé Farmaceutici S.p.A

Sponsor type

Industry

Conditions

Severe Pneumonia

Interventions

Reparixin; Standard of care

Participants

56

Sites

4

Countries

Brazil, Italy

Trials that died the same way

• A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.” (75% match in meaning)
• A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
  “This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.” (71% match in meaning)
• Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
  “The sponsor decided to terminate the study during the safety lead-in phase.” (71% match in meaning)
• Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
  “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.” (71% match in meaning)
• A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
  “The sponsor decided to terminate the study early, due to recruitment challenges for Part II and, based on the totality of data generated with a low likelihood of achieving the targeted efficacy, to open Part III.” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.